Hosted on MSN16d
Why this newly public biotech could become a force in obesity treatments
More importantly, the company already has a fill/finish and sterile injectable manufacturing arrangement lined up via a partnership with generics company Amneal Pharmaceuticals Inc. analysts Umer ...
Reuters22d
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile
Evercore ISI analyst Umer Raffat, who highlighted the inventory build in a research note on Thursday, said the so-called capitalized inventory implied $10 billion in sales, based on 2024 figures ...
Hosted on MSN25d
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Evercore ISI analyst Umer Raffat said in a report. Merck stock fell a fraction at the close to 98.36. Summit stock also dipped a fraction to 19.45. The drugs from LaNova and Summit Therapeutics ...
Business Insider1mon
Biogen (BIIB) Receives a Buy from Evercore ISI
In a report released on February 7, Umer Raffat from Evercore ISI maintained a Buy rating on Biogen (BIIB – Research Report). The company’s shares closed last Friday at $141.35. Leverage the ...